Glycan Masking of Plasmodium vivax Duffy Binding Protein for Probing Protein Binding Function and Vaccine Development

PLoS Pathogens

Volumn 9, Issue 6, 2013, Pages

  Sampath, Sowmya ^a   Carrico, Chris ^b,c   Janes, Joel ^a   Gurumoorthy, Sairam ^a   Gibson, Claire ^a   Melcher, Martin ^a   Chitnis, Chetan E ^d   Wang, Ruobing ^a   Schief, William R ^b,e   Smith, Joseph D ^a,f  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE; DUFFY BINDING PROTEIN; GLYCAN; HYBRID PROTEIN; VACCINE;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME POLYMORPHISM; ERYTHROCYTE; FLOW CYTOMETRY; GLYCOSYLATION; HISTOGRAM; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUTATION; NONHUMAN; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE HOMOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CERCOPITHECUS AETHIOPS; COS CELLS; DUFFY BLOOD-GROUP SYSTEM; GLYCOSYLATION; MALARIA VACCINES; MICE; PLASMODIUM VIVAX; PROTEIN BINDING; PROTOZOAN PROTEINS; RATS; RECEPTORS, CELL SURFACE;

PLASMODIUM VIVAX;

EID: 84879543616     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003420     Document Type: Article

References (71)

1. Chitnis CE, Sharma A, (2008) Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24: 29-34.
2. Miller LH, Mason SJ, Clyde DF, McGinniss MH, (1976) The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295: 302-304.
3. Tournamille C, Colin Y, Cartron JP, Le Van KC, (1995) Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 10: 224-228.
4. Zimmerman PA, Woolley I, Masinde GL, Miller SM, McNamara DT, et al. (1999) Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad Sci U S A 96: 13973-7.
5. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, et al. (2010) Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 107: 5967-5971.
6. Wurtz N, Mint LK, Bogreau H, Pradines B, Rogier C, et al. (2011) Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J 10: 336.
7. Kasehagen LJ, Mueller I, Kiniboro B, Bockarie MJ, Reeder JC, et al. (2007) Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS ONE 2: e336.
8. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, et al. (2011) Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci U S A 108: 20113-20118.
9. Adams JH, Hudson DE, Torii M, Ward GE, Wellems TE, et al. (1990) The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 63: 141-153.
10. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, et al. (1992) A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 89: 7085-9.
11. Fang XD, Kaslow DC, Adams JH, Miller LH, (1991) Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol 44: 125-132.
12. Chitnis CE, Miller LH, (1994) Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180: 497-506.
13. Batchelor JD, Zahm JA, Tolia NH, (2011) Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat Struct Mol Biol 18: 908-914.
14. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A, (2006) Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 439: 741-744.
15. Choe H, Moore MJ, Owens CM, Wright PL, Vasilieva N, et al. (2005) Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol 55: 1413-1422.
16. Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, et al. (1993) A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261: 1182-4.
17. Hans D, Pattnaik P, Bhattacharyya A, Shakri AR, Yazdani SS, et al. (2005) Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol Microbiol 55: 1423-1434.
18. VanBuskirk KM, Sevova E, Adams JH, (2004) Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition. Proc Natl Acad Sci U S A 101: 15754-15759.
19. Bolton MJ, Garry RF, (2011) Sequence similarity between the erythrocyte binding domain 1 of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals binding residues for the Duffy Antigen Receptor for Chemokines. Virol J 8: 45-54.
20. Chootong P, Ntumngia FB, VanBuskirk KM, Xainli J, Cole-Tobian JL, et al. (2010) Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect Immun 78: 1089-1095.
21. Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, et al. (2007) Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 4: e337.
22. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, et al. (2008) Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A 105: 8363-8368.
23. Michon P, Fraser T, Adams JH, (2000) Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun 68: 3164-3171.
24. Siddiqui AA, Xainli J, Schloegel J, Carias L, Ntumngia F, et al. (2012) Fine Specificity of Plasmodium vivax Duffy Binding Protein Binding Engagement of the Duffy Antigen on Human Erythrocytes. Infect Immun 80: 2920-2928.
25. VanBuskirk KM, Cole-Tobian JL, Baisor M, Sevova ES, Bockarie M, et al. (2004) Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies. J Infect Dis 190: 1556-1562.
26. Dvorak JA, Miller LH, Whitehouse WC, Shiroishi T, (1975) Invasion of erythrocytes by malaria merozoites. Science 187: 748-750.
27. Gilson PR, Crabb BS, (2009) Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int J Parasitol 39: 91-96.
28. Gosi P, Khusmith S, Khalambaheti T, Lanar DE, Schaecher KE, et al. (2008) Polymorphism patterns in Duffy-binding protein among Thai Plasmodium vivax isolates. Malar J 7: 112.
29. Xainli J, Adams JH, King CL, (2000) The erythrocyte binding motif of plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea. Mol Biochem Parasitol 111: 253-260.
30. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
31. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, et al. (1997) Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159: 279-289.
32. Pantophlet R, Wilson IA, Burton DR, (2003) Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 77: 5889-5901.
33. Pantophlet R, Wilson IA, Burton DR, (2004) Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng Des Sel 17: 749-758.
34. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, et al. (2005) Comparing antigenicity and immunogenicity of engineered gp120. J Virol 79: 12148-12163.
35. Selvarajah S, Puffer BA, Lee FH, Zhu P, Li Y, et al. (2008) Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses 24: 301-314.
36. Samuelson J, Banerjee S, Magnelli P, Cui J, Kelleher DJ, et al. (2005) The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc Natl Acad Sci U S A 102: 1548-1553.
37. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR, (2004) Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology 14: 103-114.
38. Mayer DC, Mu JB, Kaneko O, Duan J, Su XZ, et al. (2004) Polymorphism in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificity. Proc Natl Acad Sci U S A 101: 2518-2523.
39. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, et al. (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1: 755-768.
40. Wang R, Smith JD, Kappe SH, (2009) Advances and challenges in malaria vaccine development. Expert Rev Mol Med 11: e39.
41. Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, et al. (2005) Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25-31.
42. Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, et al. (2007) Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 25: 5166-5174.
43. Ntumngia FB, Adams JH, (2012) Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein. Clin Vaccine Immunol 19: 30-36.
44. Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE, (2004) Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22: 3727-3737.
45. Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, et al. (2011) Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 3: 93ra69.
46. Alexander S, Elder JH, (1984) Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226: 1328-1330.
47. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
48. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
49. Back NK, Smit L, de Jong JJ, Keulen W, Schutten M, et al. (1994) An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199: 431-438.
50. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637-5655.
51. Bolmstedt A, Sjolander S, Hansen JE, Akerblom L, Hemming A, et al. (1996) Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 12: 213-220.
52. McCaffrey RA, Saunders C, Hensel M, Stamatatos L, (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78: 3279-3295.
53. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
54. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343.
55. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103.
56. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6: e1001028.
57. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110.
58. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: 11483-11488.
59. Schief WR, Ban YE, Stamatatos L, (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4: 431-440.
60. Drummer HE, Jackson DC, Brown LE, (1993) Modulation of CD4+ T-cell recognition of influenza hemagglutinin by carbohydrate side chains located outside a T-cell determinant. Virology 192: 282-289.
61. Jackson DC, Drummer HE, Urge L, Otvos L Jr, Brown LE, (1994) Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones. Virology 199: 422-430.
62. Srivastava A, Gangnard S, Round A, Dechavanne S, Juillerat A, et al. (2010) Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA. Proc Natl Acad Sci U S A 107: 4884-4889.
63. Rohl CA, Strauss CE, Misura KM, Baker D, (2004) Protein structure prediction using Rosetta. Methods Enzymol 383: 66-93.
64. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
65. Shakin-Eshleman SH, Spitalnik SL, Kasturi L, (1996) The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J Biol Chem 271: 6363-6366.
66. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, et al. (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res 7: 1660-1674.
67. Sellhorn G, Caldwell Z, Mineart C, Stamatatos L, (2009) Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine 28: 430-436.
68. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, et al. (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160: 870-876.
69. Azoitei ML, Correia BE, Ban YE, Carrico C, Kalyuzhniy O, et al. (2011) Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334: 373-376.
70. Shannon CE, (1948) A Mathematical Theory of Communication. Bell Sys Tech J 3: 379-423.
71. Hodder AN, Czabotar PE, Uboldi AD, Clarke OB, Lin CS, et al. (2012) Insights into duffy binding-like domains through the crystal structure and function of the merozoite surface protein MSPDBL2 from P. falciparum. J Biol Chem 287: 32922-32939.